Stockscreener 앱 받기
7.37
43.39%
2.23
시간 외 거래:
7.58
0.21
+2.85%
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages UroGen Pharma - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel ... - Eagle-Tribune
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing R - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Shareholders that lost money on UroGen Pharma Ltd.(URGN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - PR Newswire
Kirby McInerney LLP Reminds UroGen Pharma Ltd. (URGN) - GlobeNewswire
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - marketscreener.com
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein - GlobeNewswire
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman - PR Newswire
Shareholders that lost money on UroGen Pharma Ltd. (URGN) Urged to Join Class Action – Contact ... - Bluefield Daily Telegraph
Shareholders that lost money on UroGen Pharma Ltd. (URGN) - GlobeNewswire
Nuveen Asset Management LLC Cuts Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming DeadlineURGN - PR Newswire
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who - GlobeNewswire
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire Inc.
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - marketscreener.com
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - PR Newswire
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by BNP Paribas Financial Markets - Defense World
Jane Street Group LLC Sells 4,380 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $10.00 by Analysts at Oppenheimer - Defense World
Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors - GlobeNewswire
Oppenheimer Lowers Price Target for UroGen Pharma (URGN) to $10.00 | URGN Stock News - GuruFocus
Oppenheimer Adjusts UroGen Pharma Price Target to $10 From $36, Maintains Outperform Rating - marketscreener.com
UroGen Pharma Ltd. (URGN) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 28, 2025 Deadline - ACCESS Newswire
UroGen Pharma (URGN) Target Price Adjusted by Oppenheimer | URGN Stock News - GuruFocus
Oppenheimer lowers UroGen Pharma stock price target to $10 - Investing.com India
ProShare Advisors LLC Makes New $137,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
UroGen Pharma Ltd. (URGN) Launches uTRACT Registry to Track JELMYTO Use in UTUC - Insider Monkey
UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
URGN STOCK: Suffer Losses on UroGen Pharma Ltd.? BFA Law - GlobeNewswire
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Desi - GuruFocus
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer - Business Wire
UroGen presents promising bladder cancer study results - Investing.com Australia
UroGen presents promising bladder cancer study results By Investing.com - Investing.com Canada
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) | URGN Stock News - GuruFocus
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Lost Money on UroGen Pharma Ltd. (URGN)? Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - StreetInsider
Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) InvestorsContact Levi & Korsinsky Before July 28, 2025 - ACCESS Newswire
URGN CLASS ALERT: BFA Law Notifies UroGen Pharma Ltd. Investors to Contact the Firm before the July 28 Securities Fraud Class Action Deadline - Newsfile
Deutsche Bank AG Has $333,000 Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN)Join by July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued - GlobeNewswire
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Possible Securities Fraud - ACCESS Newswire
Pharma Co. Hid Cancer Study Method Problems, Investor Claims - Law360
URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - The Malaysian Reserve
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd. - GlobeNewswire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against ... - Eagle-Tribune
Investigation Opened on Behalf of UroGen Pharma Ltd. (URGN) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Fraud Investigation Opened: Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) on Behalf of Shareholders - ACCESS Newswire
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN)Contact Levi & Korsinsky - ACCESS Newswire
Did UroGen Pharma Ltd. (URGN) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
URGN FRAUD ALERT: UroGen Pharma Ltd. Investors are Alerted to Contact BFA Law about the Pending Securities Fraud Class Action - Newsfile
URGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
0.00%
2.33%
자본화:
|
볼륨(24시간):